We use cookies for a better user experience. Read our Privacy Policy

I Agree

Dystrophic Epidermolysis Bullosa Treatment Market

Dystrophic Epidermolysis Bullosa Treatment Market (Treatment Type: Antibiotics, Corticosteroids, Opioid Analgesics, Anticonvulsant, and Others; Disease Type: Dominant Dystrophic Epidermolysis Bullosa [DDEB] and Recessive Dystrophic Epidermolysis Bullosa [RDEB]; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Entry of Novel Technologies Coupled With Increasing Focus on R&D to Bolster Market Growth

The significant rise in the number of individuals that are affected by epidermolysis bullosa (EB) is one of the primary factors that is expected to drive the global dystrophic epidermolysis bullosa treatment market in the upcoming years. At present, dystrophic epidermolysis bullosa is the second most common type of epidermolysis bullosa and as per current observations, the number of cases is likely to grow at a consistent pace in the upcoming years. Thus, the demand for dystrophic epidermolysis bullosa treatment is on the rise.

Advancements in science and increasing focus on R&D activities are likely to provide an impetus to the overall development of the global dystrophic epidermolysis bullosa treatment market during the forecast period. The entry of whole-exome sequencing has revolutionized dystrophic epidermolysis bullosa diagnostics and treatment due to the development of gene panels across various epidermolysis bullosa treatment centers. This, in turn, has accelerated diagnosis and prognostication. In addition, due to the strides taken by gene editing, gene editing-based therapies are gaining immense popularity particularly for targeted treatment. At present, researchers involved in the current dystrophic epidermolysis bullosa treatment market are increasingly focusing on gaining a better understanding of the overall pathogenic mechanism of various subtypes of epidermolysis bullosa treatment, including dystrophic epidermolysis bullosa treatment.

At the back of these factors, the global dystrophic epidermolysis bullosa treatment market is on course to attain a market value of ~US$ 710 Mn by the end of 2030.

Request a sample to get extensive insights into the Automotive Heat Shield Market

Advent of New Treatment Modalities to Drive Global Market

The increasing prevalence of epidermolysis bullosa– a set of hereditary skin blistering diseases has prompted researchers and scientists to seek newer treatment modalities – a factor that is expected to drive the global dystrophic epidermolysis bullosa treatment market during the assessment period. Furthermore, as researchers have gained immense knowledge pertaining to the genetic mutation of dystrophic epidermolysis bullosa, newer treatment modalities are currently making inroads into the global dystrophic epidermolysis bullosa treatment market. The increasing understanding of disease etio-pathogenesis is a top factor that is accelerating the development of new and cutting-edge therapy alternatives. In the current scenario, cell-based and first gene therapies are increasingly being tested in clinical trials and at the preclinical level. Moreover, the increasing knowledge of various secondary disease mechanisms has paved the way for clinical testing and development of symptom-relief therapies, including dystrophic epidermolysis bullosa treatment– a major factor that is anticipated to fuel the growth of the global dystrophic epidermolysis bullosa treatment market during the assessment period.

Strides Taken by Gene Therapy and Tissue Engineering to Fuel Adoption

Due to the notable progress made by gene therapy and tissue engineering, dystrophic epidermolysis bullosa treatment has improved by a considerable margin. Moreover, apart from these alternatives, stem cell transplantation and gene correction are some of the other treatment alternatives that are likely to gain adoption in the global dystrophic epidermolysis bullosa treatment market during the assessment period. A number of research and development activities has indicated that in vitro gene therapy of keratinocyte stem cells and transplanting the same into the skin is one of the most promising and novel treatments that is likely to gain considerable adoption in the upcoming years. Scientists and stakeholders operating in the current dystrophic epidermolysis bullosa treatment market landscape are also focusing on enhancing the clinical features in epidermolysis bullosa patients by relying on in vitro gene therapy of stem cell keratinocytes– a factor that is projected to boost the global dystrophic epidermolysis bullosa treatment market during the assessment period.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Research and Development Activities in Full Swing amid COVID-19 Pandemic

The COVID-19 pandemic is expected to have a moderate impact on the overall growth of the global dystrophic epidermolysis bullosa treatment market during the assessment period. Research and development activities for dystrophic epidermolysis bullosa treatment are underway to identify the potential threat of the novel SARS-CoV-2 virus to patients suffering from dystrophic epidermolysis bullosa. Several studies have revealed that patients suffering from epidermolysis bullosa, particularly with syndromic forms are at a higher risk of acquiring the novel COVID-19 infection.

Overall, the outbreak of the COVID-19 pandemic is expected to accelerate research and development activities, thereby opening new avenues.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Dystrophic Epidermolysis Bullosa Treatment Market

Analysts’ Viewpoint

The global dystrophic epidermolysis bullosa treatment market is expected to expand at a CAGR of ~5% during the forecast period. The market growth can be primarily attributed to increasing prevalence of epidermolysis bullosa worldwide, strides taken by gene editing, tissue engineering and stem cell technology, and rising investment for research and development. Market players are projected to focus on research and development and create awareness related to dystrophic epidermolysis bullosa treatment to gain a competitive edge.

Dystrophic Epidermolysis Bullosa Treatment Market: Overview

  • According to Transparency Market Research’s latest report on the global dystrophic epidermolysis bullosa treatment market for the historical period 2017–2018 and forecast period 2019–2027, rise in prevalence of dystrophic epidermolysis bullosa and surge in research for managing dystrophic epidermolysis bullosa are projected to drive the global dystrophic epidermolysis bullosa treatment market during the forecast period
  • According to the report, the global dystrophic epidermolysis bullosa treatment market was valued at over US$ 412 Mn in 2019 and is anticipated to expand at a CAGR of ~5% from 2020 to 2030

Rise in Prevalence of Dystrophic Epidermolysis Bullosa to Drive Demand for Dystrophic Epidermolysis Bullosa Treatment: Key Driver

  • According to the European Union, dystrophic epidermolysis bullosa is defined as a rare disease, with a prevalence of no more than 50 people per 100,000 population, whereas in the U.S., rare disease is defined as condition which affects fewer than 200,000 individuals
  • According to the National EB Registry, the overall prevalence of EB is 11.07 per one million live births. The prevalence of dominant dystrophic epidermolysis bullosa (DDEB) and recessive dystrophic epidermolysis bullosa (RDEB) is 1.49 and 1.35 per 1 million live births, respectively.
  • Data on pregnancy and EB are limited; however, a recent survey did not detect increased risk for pregnancy-related complications in women with EB
  • According to Orphanet, dystrophic epidermolysis bullosa is the second most common form of EB-epidermolysis bullosa, the first being EB simplex. The overall reported prevalence varies from 1/49,000 inhabitants in Scotland to 1/420,168 in the U.S.
  • According to the United States National Epidermolysis Bullosa Registry, the overall incidence and prevalence of epidermolysis bullosa is 19.6 and 11.07 cases per 1 million live births, respectively. The incidence and prevalence of epidermolysis bullosa simplex were 7.87 and 6 cases per 1 million live births, respectively.
  • According to the National Epidermolysis Bullosa Registry, the prevalence of epidermolysis bullosa in Norway is 54 cases per million live births, 7.8 cases per million live births in Japan, 15.4 cases per million live births in Italy, 10.3 cases per million live births in Australia, and 9.6 cases per million live births in Croatia
  • According to Springer Nature Limited (2003), the prevalence of all types of EB is estimated at 19 per million in the U.S. and the prevalence of dystrophic form of EB is 2.4 per million live births in the country

Surge in Research for Managing Dystrophic Epidermolysis Bullosa to Boost Market Growth

  • Demand for the development of newer and technologically enhanced products such as biologics and biosimilars is rising globally, owing to the treatment efficiency of these drugs. Hence, major players operating in the market invest in research to develop new drugs.
  • Rise in investment in research & development programs by key players is likely to propel the market during the forecast period
  • According to the Journal of Investigative Dermatology, the development of molecular therapies for epidermolysis bullosa is going on which addresses directly the molecular defects that lead to skin fragility, which manifests clinically as blisters and erosions. Complementary technologies, primarily in the advanced stages of preclinical research or already in early-stage clinical trials, have been reported.
  • According to the Journal of Investigative Dermatology, few researches being carried out on recessive dystrophic epidermolysis bullosa (RDEB) include grafting of genetically modified epidermal keratinocytes, localized injection of allogeneic fibroblasts into the skin, application of chimeric skin equivalents (fibroblasts from healthy donors and patient keratinocytes), allogeneic bone marrow transplantation (standard procedures), bone marrow transplantation with reduced intensity conditioning, and protein replacement by intradermal injection (type VII collagen)

Withdrawal of Drugs to Hamper Market

  • According to Physiopedia, the use of topical opiates for pain management has been proven to reduce the need of powerful systemic analgesia. Amitriptyline has also been found to be useful in both children and adults in reducing pain. For systemic treatment, no agents so far have proven to be effective in controlling blisters in patients diagnosed with EB.
  • No other medication, including phenytoin and tetracycline, have improved the blistering or epithelial disadhesion in EB. Hence, presently, there is no reliable clinical trial evidence for any type of treatment with medication.
  • In September 2017, Rival Amicus Therapeutics withdrew its AP101 drug, which was in phase III clinical study. AP101 drug was a water-based cream, which is only supposed to be applied when dressings are changed every three or four days, as recommended for EB patients. The cream was water-based and therefore a patient needed to change the dressing very frequently and failed to hit targets for wound closure in patients.
  • These factors are likely to restrain the market during the forecast period

Dystrophic Epidermolysis Bullosa Treatment Market: Competition Landscape

  • This report profiles major players in the global dystrophic epidermolysis bullosa treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • Leading players operating in the global dystrophic epidermolysis bullosa treatment market are
    • Krystal Biotech
    • Castle Creek Biosciences, Inc.
    • Abeona Therapeutics, Inc.
    • Amryt Pharma plc
    • Wings Therapeutics
    • Phoenix Tissue Repair
    • InMed Pharmaceuticals, Inc.
    • RegeneRx
    • Holostem Terapie Avanzate S.r.l.

Dystrophic Epidermolysis Bullosa Treatment Market: Key Developments

  • Key players in the global dystrophic epidermolysis bullosa treatment market are engaged in regulatory approvals, development of new therapies or products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global dystrophic epidermolysis bullosa treatment market. A few expansion strategies adopted by players operating in the global dystrophic epidermolysis bullosa treatment market are:
  • In July 2020, Krystal Biotech announced the initiation of a pivotal phase 3 GEM-3 study. It is a placebo-controlled, multi-center, double-blinded, phase 3 study of beremagene geperpavec for the treatment of dystrophic epidermolysis bullosa (DEB) patients.
  • In March 2020, Abeona Therapeutics announced that the first patient treated in a pivotal phase III clinical trial evaluating its EB-101 gene therapy for recessive dystrophic epidermolysis bullosa at Stanford University Medical Center
  • In June 2019, Fibrocell Science’s gene therapy FCX-007 received the regenerative medicine advanced therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA). FCX-007 is a gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)
  • In November 2018, Constant Pharmaceuticals announced plan to begin a development program for its compound, TXA127 for the treatment of epidermolysis bullosa in collaboration with four EB focused charities, the Epidermolysis Bullosa Medical Research Foundation (EBMRF), the Epidermolysis Bullosa Research Partnership (EBRP), Cure-EB, and DEBRA (Austria)
  • In March 2018, Krystal Biotech submitted its Investigational New Drug (IND) application with the USFDA to initiate a phase 1/2, first in-human trial of KB103. KB103 is a gene therapy engineered to deliver a human collagen-producing gene to patients with dystrophic epidermolysis bullosa.
  • The report on the global dystrophic epidermolysis bullosa treatment market discussed individual strategies, followed by company profiles of treatment providers of dystrophic epidermolysis bullosa. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global dystrophic epidermolysis bullosa treatment market.

Dystrophic Epidermolysis Bullosa Treatment Market – Segmentation

Treatment Type

  • Antibiotics
  • Corticosteroids
  • Opioid Analgesics
  • Anticonvulsant
  • Others

Disease Type

  • Dominant Dystrophic Epidermolysis Bullosa (DDEB)
  • Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Dystrophic Epidermolysis Bullosa Treatment Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of dystrophic epidermolysis bullosa treatment market?

Dystrophic epidermolysis bullosa treatment market to attain a market value of ~US$ 710 Mn by the end of 2030

What is the anticipated CAGR of the dystrophic epidermolysis bullosa treatment market in the forecast period?

Dystrophic epidermolysis bullosa treatment market is anticipated to expand at a CAGR of ~5% from 2020 to 2030

What are the key driving factors for the growth of the dystrophic epidermolysis bullosa treatment market?

Dystrophic epidermolysis bullosa treatment market is driven by rise in prevalence of dystrophic epidermolysis bullosa and surge in research for managing dystrophic epidermolysis bullosa

Which region is expected to project the highest market share in the global dystrophic epidermolysis bullosa treatment market?

North America dominated the global dystrophic epidermolysis bullosa treatment market in 2019 and the trend is anticipated to continue during the forecast period

Who are the key players in the global dystrophic epidermolysis bullosa treatment market?

Key players in the global dystrophic epidermolysis bullosa treatment market include Krystal Biotech, Castle Creek Biosciences, Inc., Abeona Therapeutics, Inc., Amryt Pharma plc, Wings Therapeutics, Phoenix Tissue Repair, InMed Pharmaceuticals, Inc., RegeneRx, and Holostem Terapie Avanzate S.r.l.

1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Dystrophic Epidermolysis Bullosa Treatment Market

4. Market Overview

        4.1. Introduction

            4.1.1. Dystrophic Epidermolysis Bullosa Treatment Market Introduction

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, 2018–2030

            4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

        5.1. Novel Therapies for Dystrophic Epidermolysis Bullosa Treatment

        5.2. Pipeline Analysis

        5.3. Potential Market of Phase 3 Pipeline Drug Therapies for Dystrophic Epidermolysis Bullosa

        5.4. Epidemiology of Dystrophic Epidermolysis Bullosa

        5.5. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)

        5.6. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Treatment Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Treatment Type, 2018–2030

            6.3.1. Antibiotics

            6.3.2. Corticosteroids

            6.3.3. Opioid Analgesics

            6.3.4. Anticonvulsant

            6.3.5. Others

        6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Disease Type

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Disease Type, 2018–2030

            7.3.1. Dominant Dystrophic Epidermolysis Bullosa

            7.3.2. Recessive Dystrophic Epidermolysis Bullosa

        7.4. Market Attractiveness Analysis, by Disease Type

8. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Distribution Channel, 2018–2030

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Others

        8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Country/Region

10. North America Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Treatment Type, 2018–2030

            10.2.1. Antibiotics

            10.2.2. Corticosteroids

            10.2.3. Opioid Analgesics

            10.2.4. Anticonvulsant

            10.2.5. Others

        10.3. Market Value Forecast, by Disease Type, 2018–2030

            10.3.1. Dominant Dystrophic Epidermolysis Bullosa

            10.3.2. Recessive Dystrophic Epidermolysis Bullosa

        10.4. Market Value Forecast, by Distribution Channel, 2018–2030

            10.4.1. Hospital Pharmacies

            10.4.2. Retail Pharmacies

            10.4.3. Others

        10.5. Market Value Forecast, by Country, 2018–2030

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Treatment Type

            10.6.2. By Disease Type

            10.6.3. By Distribution Channel

            10.6.4. By Country

11. Europe Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

        11.1.Introduction

            11.1.1. Key Findings

        11.2.Market Value Forecast, by Treatment Type, 2018–2030

            11.2.1. Antibiotics

            11.2.2. Corticosteroids

            11.2.3. Opioid Analgesics

            11.2.4. Anticonvulsant

            11.2.5. Others

        11.3.Market Value Forecast, by Disease Type, 2018–2030

            11.3.1. Dominant Dystrophic Epidermolysis Bullosa

            11.3.2. Recessive Dystrophic Epidermolysis Bullosa

        11.4.Market Value Forecast, by Distribution Channel, 2018–2030

            11.4.1. Hospital Pharmacies

            11.4.2. Retail Pharmacies

            11.4.3. Others

        11.5.Market Value Forecast, by Country/Sub-region, 2018–2030

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

        11.6.Market Attractiveness Analysis

            11.6.1. By Treatment Type

            11.6.2. By Disease Type

            11.6.3. By Distribution Channel

            11.6.4. By Country/Sub-region

12. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

        12.1.Introduction

            12.1.1. Key Findings

        12.2.Market Value Forecast, by Treatment Type, 2018–2030

            12.2.1. Antibiotics

            12.2.2. Corticosteroids

            12.2.3. Opioid Analgesics

            12.2.4. Anticonvulsant

            12.2.5. Others

        12.3.Market Value Forecast, by Disease Type, 2018–2030

            12.3.1. Dominant Dystrophic Epidermolysis Bullosa

            12.3.2. Recessive Dystrophic Epidermolysis Bullosa

        12.4.Market Value Forecast, by Distribution Channel, 2018–2030

            12.4.1. Hospital Pharmacies

            12.4.2. Retail Pharmacies

            12.4.3. Others

        12.5.Market Value Forecast, by Country/Sub-region, 2018–2030

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6.Market Attractiveness Analysis

            12.6.1. By Treatment Type

            12.6.2. By Disease Type

            12.6.3. By Distribution Channel

            12.6.4. By Country/Sub-region

13. Latin America Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

        13.1.Introduction

            13.1.1. Key Findings

        13.2.Market Value Forecast, by Treatment Type, 2018–2030

            13.2.1. Antibiotics

            13.2.2. Corticosteroids

            13.2.3. Opioid Analgesics

            13.2.4. Anticonvulsant

            13.2.5. Others

        13.3.Market Value Forecast, by Disease Type, 2018–2030

            13.3.1. Dominant Dystrophic Epidermolysis Bullosa

            13.3.2. Recessive Dystrophic Epidermolysis Bullosa

        13.4.Market Value Forecast, by Distribution Channel, 2018–2030

            13.4.1. Hospital Pharmacies

            13.4.2. Retail Pharmacies

            13.4.3. Others

        13.5.Market Value Forecast, by Country/Sub-region, 2018–2030

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6.Market Attractiveness Analysis

            13.6.1. By Treatment Type

            13.6.2. By Disease Type

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

14. Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

        14.1.Introduction

            14.1.1. Key Findings

        14.2.Market Value Forecast, by Treatment Type, 2018–2030

            14.2.1. Antibiotics

            14.2.2. Corticosteroids

            14.2.3. Opioid Analgesics

            14.2.4. Anticonvulsant

            14.2.5. Others

        14.3.Market Value Forecast, by Disease Type, 2018–2030

            14.3.1. Dominant Dystrophic Epidermolysis Bullosa

            14.3.2. Recessive Dystrophic Epidermolysis Bullosa

        14.4.Market Value Forecast, by Distribution Channel, 2018–2030

            14.4.1. Hospital Pharmacies

            14.4.2. Retail Pharmacies

            14.4.3. Others

        14.5.Market Value Forecast, by Country/Sub-region, 2018–2030

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6.Market Attractiveness Analysis

            14.6.1. By Treatment Type

            14.6.2. By Disease Type

            14.6.3. By Distribution Channel

            14.6.4. By Country/Sub-region

15. Competitive Landscape

        15.1. Company Profiles

            15.1.1. Krystal Biotech

                15.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.1.2. Growth Strategies

                15.1.1.3. SWOT Analysis

            15.1.2. Castle Creek Biosciences, Inc.

                15.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.2.2. Growth Strategies

                15.1.2.3. SWOT Analysis

            15.1.3. Abeona Therapeutics, Inc.

                15.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.3.2. Growth Strategies

                15.1.3.3. SWOT Analysis

            15.1.4. Amryt Pharma plc

                15.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.4.2. Growth Strategies

                15.1.4.3. SWOT Analysis

            15.1.5. Wings Therapeutics

                15.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.5.2. Growth Strategies

                15.1.5.3. SWOT Analysis

            15.1.6. Phoenix Tissue Repair

                15.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.6.2. Growth Strategies

                15.1.6.3. SWOT Analysis

            15.1.7. InMed Pharmaceuticals, Inc.

                15.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.7.2. Growth Strategies

                15.1.7.3. SWOT Analysis

            15.1.8. RegeneRx

                15.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.8.2. Growth Strategies

                15.1.8.3. SWOT Analysis

            15.1.9. Holostem Terapie Avanzate S.r.l.

                15.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.9.2. Growth Strategies

                15.1.9.3. SWOT Analysis

List of Tables

Table 01: Global Dystrophic Epidermolysis Bullosa Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2030

Table 02: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 03: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 04: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 05: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 06: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 07: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 08: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 09: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 10: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 11: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 12: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel ,2018–2030

Table 13: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 14: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 15: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 16: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 17: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 18: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 19: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 20: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel ,2018–2030

Table 21: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 22: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 23: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 24: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

List of Figure

Figure 01: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Disease Type, 2019

Figure 03: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Region, 2019

Figure 04: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Treatment Type, 2019

Figure 05: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Distribution Channel, 2019

Figure 06: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030

Figure 07: Global Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Treatment Type, 2020–2030

Figure 08: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Antibiotics, 2018–2030

Figure 09: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Transport Medium, 2018–2030

Figure 10: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Opioid Analgesics, 2018–2030

Figure 11: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Anticonvulsant, 2018–2030

Figure 12: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Others, 2018–2030

Figure 13: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 14: Global Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 15: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Dominant Dystrophic Epidermolysis Bullosa (DDEB), 2018–2030

Figure 16: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Recessive Dystrophic Epidermolysis Bullosa (RDEB), 2018–2030

Figure 17: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 18: Global Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 19: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2018–2030

Figure 20: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2018–2030

Figure 21: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Others, 2018–2030

Figure 22: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Region, 2019 and 2030

Figure 23: Global Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Region, 2020–2030

Figure 24: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 25: North America Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019–2030

Figure 26: North America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2030

Figure 27: North America Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030

Figure 28: North America Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019–2030

Figure 29: North America Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030

Figure 30: North America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 31: North America Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 32: North America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 33: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 34: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019–2030

Figure 35: Europe Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2030

Figure 36: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030

Figure 37: Europe Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019–2030

Figure 38: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030

Figure 39: Europe Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 40: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 41: Europe Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 42: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 43: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019–2030

Figure 44: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2030

Figure 45: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030

Figure 46: Asia Pacific Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019–2030

Figure 47: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030

Figure 48: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 49: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 50: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 51: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 52: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019–2030

Figure 53: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2030

Figure 54: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030

Figure 55: Latin America Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019–2030

Figure 56: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030

Figure 57: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 58: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 59: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 60: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 61: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019–2030

Figure 62: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2030

Figure 63: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030

Figure 64: Middle East & Africa Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019–2030

Figure 65: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030

Figure 66: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 67: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 68: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

706

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved